Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary hyperlipoproteinemia in xanthomatosis.

L W Hessel, B J Vermeer, M K Polano

    Clinica Chimica Acta; International Journal of Clinical Chemistry
    |June 15, 1976
    PubMed
    Summary

    This study on hyperlipidemia and xanthomatosis identified two patient groups based on low-density lipoprotein levels. Frederickson type II showed higher cardiovascular risk, while type III had fewer symptoms despite very high cholesterol.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Virological and Social Outcomes of HIV-Infected Adolescents and Young Adults in The Netherlands Before and After Transition to Adult Care.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America·2016
    Same author

    The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients.

    The pharmacogenomics journal·2014
    Same author

    Response to "CYP3A5 genotype, but not CYP3A4*1b, CYP3A4*22, or hematocrit, predicts tacrolimus dose requirements in Brazilian renal transplant patients".

    Clinical pharmacology and therapeutics·2013
    Same author

    Response to "pretransplantation pharmacokinetic assessments to predict posttransplantation dosing requirements in renal transplant recipients: what is known?".

    Clinical pharmacology and therapeutics·2013
    Same author

    CFTR biomarkers: time for promotion to surrogate end-point.

    The European respiratory journal·2012
    Same author

    In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.

    Clinical pharmacology and therapeutics·2012

    Area of Science:

    • Lipidology
    • Dermatology
    • Cardiology

    Background:

    • Hyperlipidemia and xanthomatosis are conditions characterized by abnormal blood lipid levels and lipid deposits in the skin.
    • Frederickson's classification system categorizes hyperlipidemias based on lipoprotein patterns.
    • Understanding these subtypes is crucial for assessing cardiovascular risk and guiding treatment.

    Purpose of the Study:

    • To analyze blood lipid profiles, clinical data, and therapeutic responses in patients with hyperlipidemia and xanthomatosis.
    • To investigate the clinical characteristics and cardiovascular disease incidence in different Frederickson types of hyperlipidemia.

    Main Methods:

    • Retrospective analysis of clinical data from 74 patients with hyperlipidemia and xanthomatosis.
    • Classification of patients into Frederickson types II and III based on low-density lipoprotein (LDL) and very low-density lipoprotein (VLDL) values.

    Related Experiment Videos

  • Evaluation of lipid profiles, presence of xanthomata, and cardiovascular disease incidence.

    • Main Results:

    • Two distinct groups emerged: Frederickson type II (elevated LDL, tendinous xanthomata, high cardiovascular disease incidence) and type III (elevated VLDL, eruptive xanthomata, palmar xanthomata, rare cardiovascular symptoms).
    • The type III group (32 patients) exhibited significantly lower cardiovascular symptom incidence despite mean cholesterol levels of 500 mg/dl.
    • Type III patients showed elevated cholesterol/triglyceride ratios in VLDL and irregular floating beta lipoproteins.

    Conclusions:

    • Frederickson's classification effectively subdivides hyperlipidemia patients with xanthomatosis into clinically distinct groups.
    • Type III hyperlipidemia, despite severe hypercholesterolemia, may present with a lower burden of cardiovascular symptoms compared to type II.
    • Further research is warranted to elucidate the mechanisms underlying the reduced cardiovascular risk in type III hyperlipidemia.